MTNB - Matinas BioPharma Holdings, Inc.
| Previous Close | 0.6300 |
| Open | 0.6200 |
| Bid | 0.6033 x 21500 |
| Ask | 0.6052 x 800 |
| Day's Range | 0.5950 - 0.6300 |
| 52 Week Range | 0.4400 - 1.5000 |
| Volume | 182,716 |
| Avg. Volume | 576,542 |
| Market Cap | 98.646M |
| Beta (3Y Monthly) | 2.88 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.1300 |
| Earnings Date | Aug 9, 2018 - Aug 10, 2018 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 4.00 |
- Simply Wall St.
Matinas BioPharma Holdings (NYSEMKT:MTNB) Is In A Good Position To Deliver On Growth Plans
Just because a business does not make any money, does not mean that the stock will go down. For example, although...
- GlobeNewswire
Matinas BioPharma to Present at the H.C. Wainwright 21st Annual Global Investment Conference
Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), a clinical stage biopharmaceutical company, today announced that Jerome D. Jabbour, Chief Executive Officer, will present a company overview, as well as host investor meetings, at the H.C. Wainwright 21st Annual Global Investment Conference. Investors interested in arranging a meeting with the Company's management during this conference should contact the conference coordinator. A live audio webcast of the presentation will be available on the Events page of the Investors section of the Company’s website (www.matinasbiopharma.com).
- Thomson Reuters StreetEvents
Edited Transcript of MTNB earnings conference call or presentation 13-Aug-19 12:00pm GMT
Q2 2019 Matinas BioPharma Holdings Inc Earnings Call
- Simply Wall St.
Is Matinas BioPharma Holdings (NYSEMKT:MTNB) Using Debt Sensibly?
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...
- Zacks
Matinas Biopharma Holdings, Inc. (MTNB) Reports Q2 Loss, Tops Revenue Estimates
Matinas Biopharma Holdings, Inc. (MTNB) delivered earnings and revenue surprises of 25.00% and 50.00%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
- GlobeNewswire
Matinas BioPharma Reports Second Quarter 2019 Financial Results and Provides Corporate Update
– MAT9001 program progressing ahead of schedule – – Additional head to head data vs. Vascepa® expected in 2020 – – NIH-funded Phase 1/2 EnACT trial of MAT2203.
- ACCESSWIRE
Matinas Biopharma Holdings, Inc. to Host Earnings Call
NEW YORK, NY / ACCESSWIRE / August 13, 2019 / Matinas Biopharma Holdings, Inc. (NYSEMKT: MTNB ) will be discussing their earnings results in their 2019 Second Quarter Earnings to be held on August 13, ...
- Zacks
Will Matinas Biopharma Holdings, Inc. (MTNB) Report Negative Earnings Next Week? What You Should Know
Matinas Biopharma Holdings, Inc. (MTNB) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- GlobeNewswire
Matinas BioPharma to Webcast Conference Call Discussing Second Quarter 2019 Operational and Financial Results on August 13, 2019
Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), a clinical-stage biopharmaceutical company, today announced that the Company will host a conference call and live webcast on Tuesday, August 13, 2019 at 8:00 a.m. ET to discuss operational and financial results for the quarter ended June 30, 2019, as well as provide a corporate update. Matinas BioPharma is a clinical-stage biopharmaceutical company focused on development of its lead product candidate, MAT9001, for the treatment of cardiovascular and metabolic conditions. The Company is actively pursuing the development of MAT9001 with the support of a world-class team of clinical key opinion leaders and regulatory consultants.
- GlobeNewswire
Matinas BioPharma Receives Qualified Infectious Disease Product (QIDP) and Fast Track Designations From U.S. FDA for MAT2203 for the Treatment of Cryptococcal Meningitis
Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), a clinical-stage biopharmaceutical company, announced today that the U.S. Food and Drug Administration (FDA) has designated MAT2203, Matinas’ proprietary oral amphotericin B product, as a Qualified Infectious Disease Product (QIDP) with Fast Track status for the treatment of cryptococcal meningitis. As previously reported, the FDA has designated MAT2203 as a QIDP with Fast Track status for three other indications, specifically, the prevention of invasive fungal infections due to immunosuppressive therapy, treatment of invasive candidiasis, and treatment of invasive aspergillus.
- Simply Wall St.
What Kind Of Investor Owns Most Of Matinas BioPharma Holdings, Inc. (NYSEMKT:MTNB)?
If you want to know who really controls Matinas BioPharma Holdings, Inc. (NYSEMKT:MTNB), then you'll have to look at...
- GlobeNewswire
Matinas BioPharma to Present at the 9th Annual LD Micro Invitational
Matinas BioPharma is a clinical-stage biopharmaceutical company focused on creating value through the streamlined development of MAT9001 for the treatment of cardiovascular and metabolic conditions and the application of its lipid nano-crystal (“LNC”) platform technology to solve complex challenges relating to the safe and effective delivery of small molecules, gene therapies, proteins, peptides and vaccines. The Company is actively pursuing the development of MAT9001 with the support of a world-class team of clinical key opinion leaders and regulatory consultants. MAT9001 is a prescription-only omega-3 fatty acid-based composition, comprised primarily of EPA and DPA, under development for hypertriglyceridemia, which has shown superiority versus Vascepa® (icosapent ethyl) in reducing serum triglycerides, Total- and Non-HDL-Cholesterol, apolipoprotein CIII and PCSK9 levels.
- Thomson Reuters StreetEvents
Edited Transcript of MTNB earnings conference call or presentation 14-May-19 12:30pm GMT
Q1 2019 Matinas BioPharma Holdings Inc Earnings Call
- GlobeNewswire
Matinas BioPharma Announces Publication of MAT2203 Preclinical Cryptococcal Meningitis Data in the American Society for Microbiology Journal, mBio
– Efficacy of oral delivery of amphotericin B (MAT2203) demonstrated comparable efficacy to IV amphotericin, with similar survival of animals and reduction in fungal burden – –.
- Simply Wall St.
Have Insiders Been Buying Matinas BioPharma Holdings, Inc. (NYSEMKT:MTNB) Shares?
We often see insiders buying up shares in companies that perform well over the long term. On the other hand, we'd be...
- GlobeNewswire
Matinas BioPharma Announces Abstract Accepted for Presentation at ASM Microbe 2019
Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), a clinical-stage biopharmaceutical company, today announced that its abstract of preclinical data of MAT2501, an orally administered, lipid nano-crystal (“LNC”) formulation of the broad spectrum aminoglycoside antibiotic agent amikacin, has been selected for two presentations at the ASM Microbe 2019 scientific meeting being held June 20–24 in San Francisco, CA.
- GlobeNewswire
Matinas BioPharma Announces a Research Collaboration with ViiV Healthcare to Evaluate Formulation of Antiviral Drug Candidates
Formulations of select antivirals will be developed using Matinas’ LNC platform delivery technology, which enables the development of a wide range of difficult-to-deliver molecules. Promising formulations will be tested in in vivo preclinical studies to identify a lead LNC-antiviral formulation to take forward in development.
- GlobeNewswire
Matinas BioPharma Provides Corporate Update and Reports First Quarter 2019 Financial Results
BEDMINSTER, N.J., May 14, 2019 -- Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), a clinical-stage biopharmaceutical company, today announced its financial results for the.
- GlobeNewswire
Matinas BioPharma to Host Conference Call and Webcast to Discuss First Quarter 2019 Operational and Financial Results on May 14, 2019
Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), a clinical-stage biopharmaceutical company, today announced that the Company will host a conference call and live audio webcast on Tuesday, May 14, 2019 at 8:30 a.m. ET to discuss operational and financial results for the quarter ended March 31, 2019 as well as provide a corporate update. Matinas BioPharma is a clinical-stage biopharmaceutical company focused on creating value through the streamlined development of its lead product candidate, MAT9001, for the treatment of cardiovascular and metabolic conditions and the application of its lipid nano-crystal (“LNC”) platform technology to solve complex challenges relating to the safe and effective delivery of small molecules, gene therapies, proteins, peptides and vaccines.
- GlobeNewswire
Matinas BioPharma to Ring NYSE Opening Bell® on May 6, 2019
BEDMINSTER, N.J., May 02, 2019 -- Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), a clinical-stage biopharmaceutical company, today announced that it has been invited to.
- GlobeNewswire
Matinas BioPharma Selected to Present at the BioNJ Ninth Annual BioPartnering Conference
Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), a clinical-stage biopharmaceutical company, today announced that Theresa Matkovits, Ph.D., Chief Development Officer of the Company, was selected to present a corporate overview and host one-on-one meetings with leading industry executives at BioNJ’s Ninth Annual BioPartnering Conference on Wednesday, May 8, 2019 during the afternoon session being held 2:00 PM – 3:00 PM ET. As part of her presentation, Dr. Matkovits will provide a corporate update and will discuss the Company’s differentiated LNC drug delivery platform. Matinas’ LNC platform technology offers an intracellular drug delivery solution with potential advantages for a range of therapeutics, including small molecules, nucleic acid polymers, proteins, peptides, vaccines, as well as the targeted delivery of gene editing technologies. Dr. Matkovits will also provide an overview of the Company’s lead anti-infective pipeline candidate, MAT2203.
- Thomson Reuters StreetEvents
Edited Transcript of MTNB earnings conference call or presentation 2-Apr-19 12:00pm GMT
Full Year 2018 Matinas BioPharma Holdings Inc Earnings Call
- GlobeNewswire
Matinas BioPharma Reports 2018 Financial Results and Provides Corporate Update
– Key focus on advancing the development of MAT9001, a potential best-in-class cardiovascular therapy in what is projected to be a new, multi-billion dollar prescription-only.
- GlobeNewswire
Matinas BioPharma to Announce Full-Year 2018 Operational and Financial Results on April 2, 2019
The call will be led by Jerome D. Jabbour, Chief Executive Officer of Matinas. Forward Looking Statements: This release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including those relating to the Company's anticipated capital and liquidity needs, strategic focus and the future development of its product candidates, including MAT9001 and MAT2203, the anticipated timing of regulatory submissions, the anticipated timing of clinical studies, the anticipated timing of regulatory interactions, the Company’s ability to identify and pursue development and partnership opportunities for its products or platform delivery technology on favorable terms, if at all, and the ability to obtain required regulatory approval and other statements that are predictive in nature, that depend upon or refer to future events or conditions.
- Business Wire
Matinas BioPharma to Present at the 31st Annual ROTH Conference
Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), a clinical-stage biopharmaceutical company, today announced that Jerome D. Jabbour, Chief Executive Officer, will present at the 31st Annual ROTH Conference on Tuesday, March 19 at 2:30 PM PT in Dana Point, CA. As part of his presentation, Mr. Jabbour will provide a corporate update and will discuss MAT9001, the Company’s proprietary prescription-only omega-3 fatty acid-based composition. Matinas is developing MAT9001 for therapeutic applications in the cardiovascular and metabolic fields with the support of a world-class team of clinical key opinion leaders and regulatory consultants.
